期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 21, 期 12, 页码 2364-2371出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2003.08.116
关键词
-
类别
资金
- NCI NIH HHS [U10 CA37422, U10 CA21661, U10 CA 32115] Funding Source: Medline
- NCRR NIH HHS [M01-RR07122] Funding Source: Medline
Purpose: This phase II, open-label, multicenter study assessed, the efficacy and safety of the potential radiation enhancer RSR13 plus cranial radiation therapy (RT) in patients with brain metastases. The primary end point was patient survival in comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis grain Metastases Database (RTOG RPA BMD). Patients and Methods: Eligibility criteria were age greater than or equal to 18 years, Karnofsky performance scare greater than or equal to 70, and brain metastases with solid tumor histology. Patients received cranial RT, 30 Gy in 10 fractions of 3 Gy each, preceded by RSR13, 50 to 100 mg/kg intravenously over 30 minutes. Univariate and multivariate comparisons of survival and cause of death were made between class It study patients and RTOG BMD patients. Results: Fifty-seven RPA class R patients were enrolled. With a minimum follow-up of 24 months, the median survival time and 1- and 2-year survival rates were 6.4 months, 230%, and 11% for the RSR13-treated patients compared, with 4.1 months, 15%, and 3% for the RTOG BMD patients (P = .0174). In an exact-matched case analysis (n = 38), median survival time for RSR13 patients was 7.3 months versus 3.4 months for the RTOG BMD Patients (P = .006). There was a 54% reduction, in the risk of death for RSR13 patients (P = .0267). RSR13-related adverse events of greater than or equal to grade 3 toxicity that occurred in more than one patient included hypoxia, headache, anemia, fatigue, hypertension, and intracranial hypertension. Conclusion: RSR13 plus cranial RT resulted in a significant improvement in survival, as well as a reduction in death due to brain metastases, compared with class If patients in the RTOG BMD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据